BSE Live
Oct 01, 16:01Prev. Close
1952.70
Open Price
1942.25
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 01, 15:50Prev. Close
1952.70
Open Price
1952.70
Bid Price (Qty.)
1959.20 (1)
Offer Price (Qty.)
0.00 (0)
Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 1,399.21 | 36.50 | 868.45 | 1,441.25 | 1,382.48 | |
Net CashFlow From Operating Activities | -827.60 | -265.44 | 625.39 | 1,108.65 | 1,131.21 | |
Net Cash Used In Investing Activities | 2.09 | 4,560.89 | -528.49 | -333.28 | -675.24 | |
Net Cash Used From Financing Activities | 787.05 | -3,906.13 | -77.46 | -520.49 | -441.78 | |
Foreign Exchange Gains / Losses | 55.89 | 17.68 | 12.39 | 17.55 | 13.62 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | -191.76 | 0.67 | 0.00 | 0.00 | |
Net Inc/Dec In Cash And Cash Equivalents | 17.44 | 215.24 | 32.50 | 272.43 | 27.82 | |
Cash And Cash Equivalents Begin of Year | 1,658.27 | 1,443.03 | 1,410.53 | 1,138.10 | 1,110.28 | |
Cash And Cash Equivalents End Of Year | 1,675.71 | 1,658.27 | 1,443.03 | 1,410.53 | 1,138.10 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015